Literature DB >> 8647185

T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding.

B Huard1, P Prigent, F Pagès, D Bruniquel, F Triebel.   

Abstract

T cell response to its antigen requires recognition by the T cell receptor together with a co-receptor molecule, either CD4 or CD8. Additional molecules have been identified that are capable of delivering the co-stimulatory signals provided by APC. Following T cell priming, a number of T cell activation antigens are expressed that may play a role in the inactivation phase of the T cell response. The lymphocyte activation gene (LAG)-3 protein and its counter-receptors, the major histocompatibility complex (MHC) class II molecules, are such activation antigens whose interaction may result in the down-regulation of the ongoing immune response. To investigate the role of LAG-3/class II molecule interaction, we produced a soluble form of LAG-3 by fusing the extracellular Ig domains of this membrane protein to the constant region of human IgG1 (LAG-3Ig). Here, we show a direct and specific binding of LAG-3Ig to class II molecules on the cell surface. In addition, we show that LAG-3/class II molecule interaction leads to the down-regulation of CD4+ Ag-specific T cell clone proliferation and cytokine secretion. This inhibitory effect is observed at the level of the effector cells and not the APC and is also found with anti-CD3 mAb, PHA + PMA or low-dose IL-2 driven stimulation in the absence of APC. These functional studies indicate that T cell MHC class II molecules down-regulate T cell proliferation following LAG-3 binding and suggest a role for LAG-3 in the control of the CD4+ T cell response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647185     DOI: 10.1002/eji.1830260533

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  40 in total

1.  LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors.

Authors:  Sandrine Buisson; Frédéric Triebel
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

Review 2.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

3.  Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.

Authors:  Jun Wang; Miguel F Sanmamed; Ila Datar; Tina Tianjiao Su; Lan Ji; Jingwei Sun; Ling Chen; Yusheng Chen; Gefeng Zhu; Weiwei Yin; Linghua Zheng; Ting Zhou; Ti Badri; Sheng Yao; Shu Zhu; Agedi Boto; Mario Sznol; Ignacio Melero; Dario A A Vignali; Kurt Schalper; Lieping Chen
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

4.  Induction of IL21 in Peripheral T Follicular Helper Cells Is an Indicator of Influenza Vaccine Response in a Previously Vaccinated HIV-Infected Pediatric Cohort.

Authors:  Lesley R de Armas; Nicola Cotugno; Suresh Pallikkuth; Li Pan; Stefano Rinaldi; M Celeste Sanchez; Louis Gonzalez; Alberto Cagigi; Paolo Rossi; Paolo Palma; Savita Pahwa
Journal:  J Immunol       Date:  2017-01-27       Impact factor: 5.422

5.  The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.

Authors:  Laëtitia Maçon-Lemaître; Frédéric Triebel
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

6.  Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.

Authors:  B Huard; R Mastrangeli; P Prigent; D Bruniquel; S Donini; N El-Tayar; B Maigret; M Dréano; F Triebel
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

7.  High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.

Authors:  Jana Kotaskova; Boris Tichy; Martin Trbusek; Hana Skuhrova Francova; Jitka Kabathova; Jitka Malcikova; Michael Doubek; Yvona Brychtova; Jiri Mayer; Sarka Pospisilova
Journal:  J Mol Diagn       Date:  2010-03-12       Impact factor: 5.568

Review 8.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

9.  Adult immuno-oncology: using past failures to inform the future.

Authors:  Maryam Rahman; W Gregory Sawyer; Scott Lindhorst; Loic P Deleyrolle; Jeffrey K Harrison; Aida Karachi; Farhad Dastmalchi; Joseph Flores-Toro; Duane A Mitchell; Michael Lim; Mark R Gilbert; David A Reardon
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

10.  Characterization of LAG-3, CTLA-4, and CD8+ TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma.

Authors:  Wenjia Wang; Donglai Chen; Yuhuan Zhao; Ting Zhao; Junmiao Wen; Yiming Mao; Chang Chen; Yonghua Sang; Yongsheng Zhang; Yongbing Chen
Journal:  Ann Transl Med       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.